不同动物模型与人类肝病病因中门静脉高压的结构与动态组分差异
研究基于肝胶原比例面积(CPA)与门静脉压力(PP)或HVPG的相关性,三维分析门静脉高压的动态组分。动物模型和不同病因患者中CPA与PP/HVPG显著相关,但相关性因模型和病因异质。高动力循环、纤维化模式、血管功能障碍/血管生成、胆汁酸、IL-6和HA被识别为动态调节因子,并在LSM验证队列中确认。
要点
- 肝纤维化是门静脉高压的主要静态组分(70%-80%),但动态组分因肝损伤类型而异。
- CPA与PP/HVPG显著相关,但相关性在不同动物模型和患者病因间存在差异。
- 高动力循环、胆汁酸、VWF-Ag、IL-6和HA提示门静脉高压的动态组分。
核心结论
- 静态纤维化对门静脉高压严重程度的相对贡献因肝损伤类型而异。
- 除高动力循环外,胆汁酸升高、VWF-Ag、IL-6和HA似乎提示患者门静脉高压存在 pronounced 动态组分。
研究设计与样本
- 动物模型:胆管结扎(n=31)、四氯化碳(n=12)、硫代乙酰胺(n=12)、胆碱缺乏高脂饮食(n=12)。
- 患者:单一病因胆汁淤积性(PBC/PSC,n=16)、酒精相关性(n=22)、代谢性(NASH,n=19)肝病。
- 基于CPA与PP/HVPG相关性识别动态组分,并在n=245患者队列中用LSM替代CPA验证。
主要发现
- CPA与动物模型PP显著相关(Rho=0.531;p<0.001),与患者HVPG显著相关(Rho=0.439;p<0.001)。
- 动物模型中,高动力循环严重程度和特定纤维化模式(门管区纤维化p=0.02;间隔宽度p=0.03)与PH严重程度相关。
- 患者中,高动力循环(p=0.04)、血管功能障碍/血管生成(VWF-Ag:p=0.03;sVEGFR1:p=0.03)和胆汁酸(p=0.04)是PH的动态调节因子。
- LSM-HVPG验证队列确认上述结果,并提示IL-6(p=0.008)和HA(p<0.001)为动态PH组分。
临床怎么用
- 评估门静脉高压时需考虑病因特异性,静态纤维化指标不能完全反映压力严重程度。
- 可关注高动力循环、胆汁酸、VWF-Ag、IL-6和HA等动态标志物辅助判断门静脉高压。
局限性
- 动物模型与人类肝病存在种属差异,需谨慎外推。
- 验证队列使用LSM替代CPA,可能引入测量偏差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Liver fibrosis is the static and main (70%-80%) component of portal hypertension (PH). We investigated dynamic components of PH by a three-dimensional analysis based on correlation of hepatic collagen proportionate area (CPA) with portal pressure (PP) in animals or HVPG in patients. APPROACH AND RESULTS: Different animal models (bile duct ligation: n = 31, carbon tetrachloride: n = 12, thioacetamide: n = 12, choline-deficient high-fat diet: n = 12) and patients with a confirmed single etiology of cholestatic (primary biliary cholangitis/primary sclerosing cholangitis: n = 16), alcohol-associated (n = 22), and metabolic (NASH: n = 19) liver disease underwent CPA quantification on liver specimens/biopsies. Based on CPA-to-PP/HVPG correlation, potential dynamic components were identified in subgroups of animals/patients with lower-than-expected and higher-than-expected PP/HVPG. Dynamic PH components were validated in a patient cohort (n = 245) using liver stiffness measurement (LSM) instead of CPA. CPA significantly correlated with PP in animal models (Rho = 0.531; p < 0.001) and HVPG in patients (Rho = 0.439; p < 0.001). Correlation of CPA with PP/HVPG varied across different animal models and etiologies in patients. In models, severity of hyperdynamic circulation and specific fibrosis pattern (portal fibrosis: p = 0.02; septa width: p = 0.03) were associated with PH severity. In patients, hyperdynamic circulation (p = 0.04), vascular dysfunction/angiogenesis (VWF-Ag: p = 0.03; soluble vascular endothelial growth factor receptor 1: p = 0.03), and bile acids (p = 0.04) were dynamic modulators of PH. The LSM-HVPG validation cohort confirmed these and also indicated IL-6 (p = 0.008) and hyaluronic acid (HA: p < 0.001) as dynamic PH components. CONCLUSIONS: The relative contribution of "static" fibrosis on PH severity varies by type of liver injury. Next to hyperdynamic circulation, increased bile acids, VWF-Ag, IL-6, and HA seem to indicate a pronounced dynamic component of PH in patients.
引用
- Königshofer P, Hofer BS, Brusilovskaya K, et al. Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. Hepatology. 2021. PMID: 34716927. doi:10.1002/hep.32220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。